Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study ...

Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Abbott and MSD Pharmaceuticals partner to distribute oral anti-diabetic medicines in India, benefiting millions with Type 2 ...

Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the ...

Abbott and MSD Pharmaceuticals announced a partnership to distribute oral anti-diabetic medicines, specifically sitagliptin, ...

Abbott & MSD ink strategic pact to distribute innovative oral anti-diabetic medicines in India: Our Bureau, Bengaluru Thursday, June 19, 2025, 12:30 Hrs [IST] Abbott and MSD Pharm ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Abbott and MSD Pharmaceuticals announced a distribution pact for oral anti-diabetic medicines like Januvia, Janumet, and ...